

## Integrated Analysis Plan

**Study Number:** MS200095\_0051

**Clinical Study Protocol Title:** Phase I, Open-label, Single-sequence, Cross-over Study of the Effect of Multiple Doses of Carbamazepine on Single-dose Tepotinib Pharmacokinetics in Healthy Participants

**Study Phase:** Phase I

**Merck Compound:** Tepotinib

**Protocol Version:** 03 Sep 2021/Version 1.0

**Integrated Analysis Plan  
Author:**

**Coordinating Author**

Biostatistics, Merck

PPD

**Function**

**Author(s) / Data Analyst(s)**

Biostatistics, PPD

PPD

**Integrated Analysis Plan  
Date and Version:**

11 Jan 2022 / Version Final 1.0

**Integrated Analysis Plan  
Reviewers:**

**Function**

**Name**

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

PPD

**Confidential**

This document is the property of Merck KGaA, Darmstadt, Germany, or one of its affiliated companies. It is intended for restricted use only and may not - in full or part - be passed on, reproduced, published or used without express permission of Merck KGaA, Darmstadt, Germany or its affiliate.

Copyright © [2021] by Merck KGaA, Darmstadt, Germany or its affiliate. All rights reserved.

## **Approval Page**

### **Integrated Analysis Plan: MS200095\_0051**

Phase I, Open-label, Single-sequence, Cross-over Study of the Effect of Multiple Doses of Carbamazepine on Single-dose Tepotinib Pharmacokinetics in Healthy Participants

Approval of the IAP by all Merck Data Analysis Responsible has to be documented within EDMS via eSignature. With the approval, the Merck responsible for each of the analysis also takes responsibility that all reviewers' comments are addressed adequately.

By using eSignature, the signature will appear at the end of the document.

<b>1</b>	<b>Table of Contents</b>	
Approval Page		2
1	Table of Contents	3
2	List of Abbreviations and Definition of Terms	5
3	Modification History	6
4	Purpose of the Integrated Analysis Plan	6
5	Objectives and Endpoints	7
6	Overview of Planned Analyses	7
7	Changes to the Planned Analyses in the Clinical Study Protocol	7
8	Analysis Sets and Subgroups	8
8.1	Definition of Analysis Sets	8
8.2	Subgroup Definition and Parameterization	8
9	General Specifications for Data Analyses	8
9.1	Definition of Baseline and Change from Baseline	9
9.2	Study Day / Study Intervention Day	9
9.3	Definition of Duration and ‘Time Since’ Variables	9
9.4	Imputation of Missing Data	10
10	Study Participants	10
10.1	Disposition of Participants and Discontinuations	10
10.2	Protocol Deviations / Exclusion from Analysis Sets	11
10.2.1	Important Protocol Deviations	11
10.2.2	Reasons Leading to the Exclusion from an Analysis Set	12
11	Demographics and Other Baseline Characteristics	12
11.1	Demographics	12
11.2	Medical History	12
11.3	Other Baseline Characteristics	12
12	Previous or Concomitant Therapies/Procedures	12
13	Study Intervention: Compliance and Exposure	13
14	Efficacy Analyses	13
15	Safety Analyses	14
15.1	Adverse Events	14
15.1.1	All Adverse Events	14

15.1.2	Adverse Events Leading to Discontinuation of Study Intervention ...	15
15.2	Deaths, Other Serious Adverse Events, and Other Significant Adverse Events .....	16
15.2.1	Deaths .....	16
15.2.2	Serious Adverse Events .....	16
15.2.3	Other Significant Adverse Events .....	16
15.3	Clinical Laboratory Evaluation.....	16
15.4	Vital Signs .....	17
15.5	Other Safety or Tolerability Evaluations .....	17
16	Analyses of Other Endpoints/Estimands .....	18
16.1	Pharmacokinetics .....	18
16.1.1	Descriptive Statistics of PK Concentration Data .....	18
16.1.2	Descriptive Statistics of PK Parameter Data .....	18
16.1.3	Statistical Analysis of PK Parameter Data .....	19
16.1.4	General Specifications for PK Concentration and PK Parameter Data.....	20
16.1.5	Estimation of Pharmacokinetic Parameters .....	20
16.1.5.1	Estimation of Pharmacokinetic Parameters in Plasma .....	21
16.1.6	Presentation of PK Concentration and PK Parameter Data .....	23
16.1.6.1	Listings and Tables .....	23
16.1.6.2	Graphical Summaries and Individual plots (PK Analysis Set).....	24
17	References.....	25
18	Appendices .....	26

## 2 List of Abbreviations and Definition of Terms

ADaM	Analysis Data Model
AE	Adverse Event
ANOVA	Analysis of VARIANCE
BLQ	Below Lower Limit of Quantification
CDISC	Clinical Data Interchange Standards Consortium
CI	Confidence Interval
CR	Complete Response
eCRF	electronic Case Report Form
CSR	Clinical Study Report
ECG	Electrocardiogram
IAP	Integrated Analysis Plan
ICH	International Conference on Harmonization
MCAR	Missing Completely At Random
MedDRA	Medical Dictionary for Regulatory Activities
PT	Preferred Term
PK	Pharmacokinetics
SAE	Serious Adverse Event
SDTM	Study Data Tabulation Model
SOC	System Organ Class
TEAE	Treatment-Emergent Adverse Event
TLF	Tables, Listings, and Figures
WHO-DD	World Health Organization Drug Dictionary

### 3 Modification History

Unique Identifier for Version	Date of IAP Version	Author	Changes from the Previous Version
Final 1.0	11-Jan-2021	PPD	Initial version.

### 4 Purpose of the Integrated Analysis Plan

The purpose of this IAP is to document technical and detailed specifications for the final analysis of data collected for protocol MS200095\_0051. Results of the analyses described in this IAP will be included in the CSR. Additionally, the planned analyses identified in this IAP may be included in regulatory submissions or future manuscripts. Any post-hoc, or unplanned analyses performed to provide results for inclusion in the CSR but not identified in this prospective IAP will be clearly identified in the CSR.

The IAP is based upon Section 9 (Statistical considerations) of the study protocol and protocol amendments and is prepared in compliance with ICH E9. It describes analyses planned in the protocol and protocol amendments.

The wording used in this IAP is chosen to best match the respective wording in the study protocol template, the Clinical Study Report (CSR) template, CDISC requirements and special requirements for table layouts. Therefore, the following approach is used:

Generally, the term ‘participant’ will be used instead of ‘subject’ or ‘patient’. However, in tables and listings the term ‘subject’ will be used to match CDISC requirements, except for in-text tables where ‘participant’ will be used to match the CSR and protocol templates. Similarly, the term ‘study intervention’ will be used in this document instead of ‘treatment’ to match protocol and CSR templates, however, tables and listings will use ‘treatment’ for brevity reasons. Exceptions from this rule are commonly used terms like “on-treatment”, “treatment-emergent”, “treatment policy”, “subject-years”, “by-subject”, or names of eCRF pages like “Treatment Termination” page.

## 5 Objectives and Endpoints

Objectives	Endpoints	Ref #
<b>Primary</b>		
To investigate the effect of multiple doses of carbamazepine on the PK of a single dose of tepotinib in healthy participants	Plasma tepotinib: AUC <sub>0-∞</sub> , AUC <sub>0-last</sub> and C <sub>max</sub>	1
<b>Secondary</b>		
To assess the safety and tolerability of tepotinib when administered together with carbamazepine in healthy participants	<ul style="list-style-type: none"> <li>Nature, occurrence, severity, and seriousness of TEAEs</li> <li>Absolute values and changes in safety laboratory tests</li> <li>Single 12-lead ECGs evaluated by Investigator</li> <li>Vital signs assessed from time of first dose to end of study participation</li> </ul>	2
To characterize the effect of carbamazepine on additional tepotinib PK parameters in healthy participants	Plasma tepotinib: CL/F, V <sub>z</sub> /F, t <sub>max</sub> , t <sub>1/2</sub>	3
<b>CCI</b>		
[REDACTED]	[REDACTED]	■
[REDACTED]	[REDACTED]	■
[REDACTED]	[REDACTED]	■
[REDACTED]	[REDACTED]	■

ECG=electrocardiogram, MR metabolic ratio, PK=pharmacokinetics, TEAE=treatment emergent adverse events.

## 6 Overview of Planned Analyses

The final, planned analyses identified in the CSP and in this IAP will be performed after the last participant has completed the last visit and after all data queries resolved as well as the database locked.

A data review meeting will be held prior to database lock for the final analysis. In addition, no database can be locked until this IAP has been approved.

## 7 Changes to the Planned Analyses in the Clinical Study Protocol

There are no changes to the planned analyses in the clinical study protocol.



## 8 Analysis Sets and Subgroups

### 8.1 Definition of Analysis Sets

Analysis Set	Description
Screening (SCR)	All participants, who provided informed consent, regardless of the participant's enrollment and study intervention status in the study.
Safety (SAF)	All participants, who were administered any dose of any study intervention. Analyses will consider participants as treated.
Pharmacokinetic (PK)	The PK Analysis Set is a subset of the SAF, and the PK population will include all participants: Who have completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results. With adequate study intervention compliance. With evaluable PK data, i.e., at least one non-missing value for primary endpoints. If participants received prohibited concomitant therapy or medicines, as specified in Section 6.8.3 of the CSP, they will be excluded from the PK population. All PK analyses will be based on this analysis set.

### 8.2 Subgroup Definition and Parameterization

Not applicable.

## 9 General Specifications for Data Analyses

The results of this study will be reported using summary tables, figures, and data listings, as appropriate. All data will be summarized by study intervention and/or scheduled time point, as applicable.

### Listings

In the individual participant data listing all individual data will be listed as measured. Repeated and unscheduled measurements will be included in the listings. All listings will be sorted by subject ID, study intervention, and nominal time point, as appropriate.

### Tables and Descriptive Statistics

All data will be summarized by study intervention and nominal time point, as appropriate. Repeated and unscheduled measurements included in the listings will not be used for statistical analyses or summaries, unless the repeated measurement was performed due to unreliable values/technical reasons, e.g., clotted samples.

Unless otherwise specified, continuous variables will be summarized using descriptive statistics, i.e. the number of participants with non-missing values (n), the number of participants with missing values (nmiss), mean, standard deviation, median, 25th percentile (Q1) and 75th percentile (Q3), minimum, and maximum. If there are no missing values the number of participants with missing values should be indicated by a 0. Mean, Median, Q1, Q3, Min, Max will have the same precision



as the SDTM data (decimal places). SD will be presented with one decimal place more than the mean.

Qualitative variables will be summarized by frequency counts and percentages. Unless otherwise stated the calculation of proportions will be based on the number of participants of the analysis set of interest that received the respective study intervention for AE and PK tables and for all other evaluations the analysis set of interest [N]. Therefore, counts of missing observations will be included in the denominator and presented as a separate category.

Study Day 1 for this study is defined as the start date of study intervention.

The following labels will be used for the study interventions in tables and listings, if not stated otherwise:

Tepotinib:	Tepotinib: 500 mg on Day 1
Carbamazepine:	Carbamazepine: 100 mg BID on Days 8-9, 200 mg BID on Days 10-11, and 300 mg BID on Days 12-25
Carbamazepine+Tepotinib:	Carbamazepine: 300 mg Carbamazepine BID on Days 26-32 plus Tepotinib: 500 mg on Day 26

Study interventions will be ordered in tables, listings and figures as above.

All statistical analyses will be performed using SAS® Software version 9.4 or higher.

## **9.1 Definition of Baseline and Change from Baseline**

If not otherwise specified, 'baseline' refers to the last scheduled measurement before administration of first study intervention.

However, if a participant is missing the baseline collection, the previous non-missing evaluation could become the baseline value (e.g. from Screening). If no baseline or previous to baseline evaluations exist, then the baseline value will be treated as missing.

Absolute changes from baseline are defined as

$$\text{absolute change} = \text{visit value} - \text{baseline value}$$

## **9.2 Study Day / Study Intervention Day**

Day 1 is the day of start of study intervention, the day before is Day -1 (no Day 0 is defined). Study day is defined relative to Day 1.

## **9.3 Definition of Duration and 'Time Since' Variables**

The following definitions and calculations of duration, as applicable, will be applied:

- Duration of adverse event (AE) (in days hh:mm) = end date and time - start date and time of the AE, if missing time for either the beginning or end then = end date – start date + 1; in case of multiple records for the same AE, the duration will be calculated over all these records
- Days hh:mm from dosing (onset post administration) = start date and time of the event - date and time of last dose administration of tepotinib or Carbamazepine (calculated for each intervention, for TEAEs), if missing time for either the dosing or event then days hh:mm from dosing = event start date – date of dose administration + 1
- Relative Day in study of AE = start date of the event – date of first admin + 1 (for AEs on or after the day of dosing)
- Relative Day in study of AE = start date of the event – date of first admin (for events before the day of dosing of the study only)

## **9.4 Imputation of Missing Data**

In this Phase I PK study, missing observations will be assumed to be missing completely at random (MCAR). No action will be taken to handle missing data. A participant who withdraws prior to the last planned observation in a study period will be included in the analyses up to the time of discontinuation.

## **10 Study Participants**

The subsections in this section include specifications for reporting participant disposition and study intervention/study discontinuations. Additionally, procedures for reporting protocol deviations are provided.

### **10.1 Disposition of Participants and Discontinuations**

The following will be presented in a summary table:

- Total number of participants screened (i.e., participants who gave informed consent)
- Number of screened participants who discontinued from the study prior to first dosing overall and grouped by the main reason for discontinuation:
  - Participant did not meet all eligibility criteria
  - Withdrew consent
  - Other (COVID-19-related and COVID-19-non-related)
- Number of treated participants
- Number and percentage of treated participants who completed study
- Number and percentage of treated participants who discontinued the study or study intervention, with the primary reason of discontinuation:
  - Adverse event
  - Lost to follow-up

- Protocol non-compliance
- Death
- Withdrew consent
- Other (COVID-19-related and COVID-19-non-related)

The number and percentage of participants will be presented by group of study intervention and total, where applicable. Percentages will be presented with respect to the number of treated participants, where applicable.

A listing of discontinued participants will be provided.

A listing of participants affected by the COVID-19 related study disruption by unique participant identifier will also be provided.

## **10.2 Protocol Deviations / Exclusion from Analysis Sets**

### **10.2.1 Important Protocol Deviations**

Listings of important protocol deviations will be provided including the date and relative day in relation to first dosing in the study. A distinction will be made between important protocol deviations due to COVID-19 versus not due to COVID-19. The respective important protocol deviations will be flagged accordingly.

Important protocol deviations or important events that might have an effect on PK include, but may not be limited to the following:

- Adverse events like diarrhea etc. (these instances will be discussed on a case-by case basis)
- Vomiting after administration following oral dosing (these instances will be discussed in alignment with applicable regulatory guidelines on a case-by case basis)
- Sample processing errors that may lead to inaccurate bioanalytical results
- Inaccurate dosing or dosing errors (e.g. dose administration delayed, dose change or missed doses)
- Pre-dose or trough sample collected after the actual dosing
- Non-compliance with food and drink requirements (e.g. non-fasted, incomplete meal consumption, caffeine intake)
- Concomitant medication, vitamins, dietary or herbal supplements

Should one or more of these events be available at the Data Review Meeting, its implication for PK evaluation will be discussed and agreed amongst relevant study team members (e.g. Sponsor Clinical Pharmacology/Biostatistics/Clinical Pharmacokinetics & Pharmacodynamics team representative). Appropriate action will be taken such as flagging individual values to be excluded from analysis.

## **10.2.2 Reasons Leading to the Exclusion from an Analysis Set**

If participants are excluded from the PK Analysis Set, the reasons for exclusion will be listed.

Reasons for excluding individual PK concentrations will also be listed separately and flagged in the main listing.

## **11 Demographics and Other Baseline Characteristics**

Demographics and baseline characteristics will be presented for the SAF.

### **11.1 Demographics**

Descriptive statistics will be presented for age, height, weight, and body mass index (BMI). Frequency counts and percentages will be presented for sex, race, and ethnicity. The summary will be performed overall.

BMI (kg/m<sup>2</sup>) will be derived (i.e., not taken directly from the database) according to the following formula:

$$\text{BMI [kg/m}^2\text{]} = \frac{\text{weight [kg]}}{\text{height[cm]}^2} \times 10000$$

### **11.2 Medical History**

Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), most current version at time of data base lock, and listed.

The medical history will be listed by participant including preferred term (PT) as event category and system organ class (SOC) body term as Body System category.

### **11.3 Other Baseline Characteristics**

Other baseline measurements, such as virus screen, alcohol and drugs of abuse screen, pregnancy test in women, nicotine and alcohol consumption, will be listed.

Baseline characteristics with respect to vital signs, physical examinations, and hematology/biochemistry will be part of Section 15 (Safety Analysis).

## **12 Previous or Concomitant Therapies/Procedures**

Medications will be presented for the SAF.

Previous medications are defined as any medication discontinued prior to the administration of first study intervention. Concomitant medications are defined as any medication taken during the course of the study, with a starting date greater than or equal to the administration of first study

intervention, or with a starting date prior to the administration of first study intervention and ongoing at the time of the first administration of study intervention.

The World Health Organization Drug dictionary (WHO-DD), most current version at time of database lock, will be used for coding of prior and concomitant medications and they will be described using Preferred Term (PT) as applicable.

Previous and concomitant medications will be listed. Concomitant procedures, if any, will also be listed.

### **13 Study Intervention: Compliance and Exposure**

The dosing of each participant is monitored by the study nurse or investigator. A listing of date and time of each drug administration and each blood sampling, including time deviations as well as measured plasma concentrations, will be provided sorted by participant. Information on meal intake will be listed by participant, if provided.

### **14 Efficacy Analyses**

Not applicable.



## 15 Safety Analyses

This section includes specifications for summarizing safety endpoints that are common across clinical studies such as adverse events, laboratory tests and vital signs.

All safety analyses will be performed for the Safety Analysis Set and will be presented by study intervention and nominal timepoint, as appropriate.

Safety analyses will be done according to the as-treated principle.

### 15.1 Adverse Events

All AEs recorded during the course of the study will be coded with the MedDRA, latest version at time of data base lock, and assigned to a SOC and a PT.

Treatment-emergent AEs (TEAEs) are those events with onset dates on or after the first administration of study intervention on Day 1. Any AE occurring before the administration of study intervention on Day 1 and resolved before administration of study intervention or not worsening after administration of study intervention on Day 1 will be included in the AE listings but will not be included in the summary tables (unless otherwise stated). These will be referred to as “pre-treatment” AEs. An AE occurring after administration of any study intervention will be counted towards the last intervention received before the onset, even if the event is not resolved at the beginning of the following intervention. An AE that worsens after a later intervention period will be counted towards both study interventions.

In case AE-related dates are partial, the available information will be used in a conservative approach to determine whether the AE is treatment-emergent.

All analyses described in Section 15.1 will be based on TEAEs if not otherwise specified. The AE listings will include all AEs (whether treatment-emergent or not). AEs outside the on-treatment period will be flagged in the listings.

Unless otherwise specified, TEAEs will be summarized, by number and percentage of participants with the TEAE in the category of interest, as well as the number of events, in total and by study intervention group, primary SOC and PT in alphabetical order for SOC and decreasing overall frequency for PT.

If an event was reported more than once due to change in intensity and change in relationship, the worst severity and the worst relationship to trial treatment will be tabulated.

Each participant will be counted only once within each SOC or PT.

#### 15.1.1 All Adverse Events

Number of treatment-emergent AEs and number of participants experiencing TEAEs will be summarized for Tepotinib, Carbamazepine, Carbamazepine+Tepotinib and overall, each in tables with:

- The number and percentage of participants with any TEAE, any related TEAE, any tepotinib-related TEAE, any carbamazepine-related TEAE, any serious TEAE, any related serious TEAE, any tepotinib-related serious TEAE, any carbamazepine-related serious TEAE, any severe TEAE, any related severe TEAE, any tepotinib-related severe TEAE, any carbamazepine-related severe TEAE, any AEs of special interest (AESI), any TEAE leading to death, any related TEAE leading to death, any tepotinib-related TEAE leading to death, any carbamazepine-related TEAE leading to death, any TEAE leading to study discontinuation
- The number and percentage of participants with at least one TEAE and the number of events by SOC and PT.
- The number and percentage of participants with TEAEs excluding SAEs and the number of events, with frequency  $\geq 5\%$  in any study intervention arm by SOC and PT
- The number and percentage of participants with at least one TEAE and the number of events by severity, SOC, and PT
- The number and percentage of participants with at least one related TEAE, tepotinib-related TEAE, carbamazepine-related TEAE and the number of events by SOC and PT
- The number and percentage of participants with at least one AESI recorded and the number of events by SOC and PT.

Unless otherwise stated, AEs will be displayed with SOC terms sorted alphabetically and PTs within each SOC term sorted in descending overall frequency.

For determining incidence counts, within each level of TEAE term, if a participant experiences more than one occurrence, the participant will only be counted once for that TEAE.

Adverse events related to any study intervention are those events with relationship missing, unknown or yes.

In case a participant had events with missing and non-missing severity, the maximum non-missing severity will be displayed.

### **15.1.2 Adverse Events Leading to Discontinuation of Study Intervention**

A listing of TEAEs leading to discontinuation of study intervention, or discontinuation of study, if any, will be provided.

The frequency (number and percentage) of participants with TEAEs leading to permanent discontinuation of each study intervention by study intervention will also be provided in a table.



## **15.2 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events**

### **15.2.1 Deaths**

A listing of deaths, if any, will be provided.

### **15.2.2 Serious Adverse Events**

A listing of serious AEs (SAEs), if any, will be provided.

Summary table of the number and percentage of participants with at least one SAE by SOC and PT will also be provided.

### **15.2.3 Other Significant Adverse Events**

The following AESIs were defined:

- AEs suggestive of drug-induced liver injury including hepatic/liver failure and hepatitis (noninfectious) are considered AESIs.

More information can be found in the CSP, Section 8.3.7.

AESIs will be identified in the AE listings. Summary table of the number and percentage of participants with at least one AESI by SOC and PT will also be provided.

## **15.3 Clinical Laboratory Evaluation**

Listings and summary statistics at each assessment time will be presented using the Système International (SI) units. Normal ranges will be provided by the laboratory department, and out of range flags will be calculated based on the normal ranges. Laboratory data not transferred from the central laboratory in SI units will be converted to SI units before processing. Both original units and SI units will be provided in the SDTM domain.

Safety laboratory parameters are separated into:

- Hematology (including coagulation)
- Biochemistry
- Urinalysis
- Other tests

Hematology and biochemistry will be summarized by study intervention and time point using descriptive statistics for baseline (see definition in Section 9), each evaluation during the study, and change from baseline to each evaluation.

Summaries will include all assessments from screening on.

Listings of abnormal test results (low and high) will also be provided.

## **15.4 Vital Signs**

Vital signs data will be summarized by study intervention and time point using descriptive statistics for baseline (see definition in Section 9), each evaluation during the study, and change from baseline to each evaluation. Listing of vital signs data will be provided.

Vital sign summaries will include all vital sign assessments from screening onwards. All vital sign assessments will be listed, and those collected outside the on-treatment period will be flagged in the listing.

## **15.5 Other Safety or Tolerability Evaluations**

Safety ECG data will be summarized by study intervention and time point using descriptive statistics for baseline (see definition in Section 9), each evaluation during the study, and change from baseline to each evaluation. Listing of safety ECG data will be provided.

ECG summaries will include all ECG assessments from screening onwards. All ECG assessments will be listed.

The analysis of QT data is complicated by the fact that the QT interval is highly correlated with heart rate. Because of this correlation, formulas are routinely used to obtain a corrected value, denoted QTc, which is independent of heart rate. This QTc interval is intended to represent the QT interval at a standardized heart rate. Several correction formulas have been proposed in the literature. The QT interval will be corrected for heart rate by the Fridericia's formula, QTcF, is defined as

$$QTcF = \frac{QT}{\sqrt[3]{RR}},$$

where RR represents the RR interval of the ECG, in seconds, and can be estimated as 60/Heart Rate.

Investigator reported interpretation results will also be tabulated by study intervention and time point using the number and percentage of participants for each interpretation category (Normal, Abnormal Not Clinically Significant [NCS], Abnormal Clinically Significant [CS]).

## 16 Analyses of Other Endpoints/Estimands

### 16.1 Pharmacokinetics

PK evaluation will be performed by PPD .

All statistical analyses and descriptive summaries of PK data will be performed on the PK Analysis Set.

#### 16.1.1 Descriptive Statistics of PK Concentration Data

PK measurements of tepotinib and its metabolites (MSC2571109A and MSC2571107A) as well as carbamazepine and its metabolite carbamazepine-10,11-epoxide in plasma will be descriptively summarized using number of non-missing observations (n), arithmetic mean (Mean), standard deviation (SD), coefficient of variation (CV%), minimum (Min), median (Median) and maximum (Max).

Descriptive statistics will only be calculated for  $n > 2$  in which a measurement of below lower limit of quantification (BLQ) represents a valid measurement and will be taken as zero for summary statistics of PK concentration data.

Any mean or median value that is below the lower limit of quantification will be shown as BLQ.

Descriptive statistics of PK concentration data will be calculated using values with the same precision as the source data and rounded for reporting purposes only. In export datasets, as well as in the SDTM PC domain, PK concentrations will be provided with full precision and will not be rounded.

The following conventions will be applied when reporting descriptive statistics of PK concentration data:

N	0 decimal place
Mean, Min, Median, Max:	3 significant digits
SD:	4 significant digits
CV%:	1 decimal place

#### 16.1.2 Descriptive Statistics of PK Parameter Data

PK parameter data of tepotinib and its metabolites (MSC2571109A and MSC2571107A) on Days 1 and 26 will be descriptively summarized using: number of non-missing observations (n), arithmetic mean (Mean), standard deviation (SD), coefficient of variation (CV%), minimum (Min), median (Median), maximum (Max), geometric mean (GeoMean), the geometric coefficient of variation (GeoCV) and the 95% confidence interval for the GeoMean (LCI 95% GM, UCI 95%

GM). For PK parameters related to time (e.g. t<sub>max</sub>, t<sub>lag</sub>, t<sub>last</sub>), only n, Min, Median, and Max may be reported.

Descriptive statistics will only be calculated for a PK parameter when n>2.

PK parameters read directly from the measurements (i.e. C<sub>max</sub>) will be reported with the same precision as the source data. All other PK parameters will be reported to 3 significant figures. In export datasets, as well as in the SDTM PP domain, PK parameters will be provided with full precision and will not be rounded. Descriptive statistics of PK parameter data will be calculated using full precision values and rounded for reporting purposes only.

The following conventions will be applied when reporting descriptive statistics of PK parameter data:

n	0 decimal place
Mean, Min, Median, Max, GeoMean, 95% CI:	3 significant digits
SD:	4 significant digits
CV%, GeoCV%:	1 decimal place

### 16.1.3 Statistical Analysis of PK Parameter Data

#### Analysis of Primary Endpoints

The effect of co-administration of Carbamazepine on tepotinib exposure will be assessed. A general linear model with a fixed effect for TREATMENT and a random effect for SUBJECT will be applied to the log-transformed PK parameters C<sub>max</sub>, AUC<sub>0-tlast</sub> and AUC<sub>0-∞</sub> based on the PK analysis set. Treatment differences on the log scale of tepotinib with Carbamazepine versus tepotinib alone (Day 26 versus Day 1) will be estimated for the C<sub>max</sub>, AUC<sub>0-tlast</sub> and AUC<sub>0-∞</sub> together with their 90% CIs. Point estimates and CIs will be back transformed to the original scale for presentation.

The analysis will be repeated with both subject and treatment as fixed effects.

CCI



#### **16.1.4 General Specifications for PK Concentration and PK Parameter Data**

Predose samples that occur before the first drug administration will be assigned a time of 0 hours, as if the sample had been taken simultaneously with the study intervention administration. Same applies to the pre-dose sample after multiple doses.

Predose or trough samples which have been taken after the subsequent dosing will be reported as a protocol deviation. The resulting concentrations will be included in concentration listings but excluded from descriptive statistics of concentrations.

Values BLQ will be taken as zero for summary statistics of PK concentration data, PK parameter estimation (e.g. AUC) and for graphical presentations.

Missing concentrations (e.g. no sample, insufficient sample volume for analysis, no result or result not valid) will be reported and used generally as “N.R.”. A participant who withdraws prior to the last planned observation will be included in the analyses up to the time of discontinuation if still included in the PK analysis set.

If samples are collected outside of 10% of the PK sampling time windows defined in the CSP in section 8.4, these will be included in the PK parameter estimation (NCA) but will be excluded from the concentration summary and mean/median concentration plots.

PK concentrations which are erroneous due to a sampling processing or analytical error (as documented in the bioanalytical report) may be excluded from the PK analysis if agreed by the Sponsor. In this case the rationale for exclusion will be provided in the CSR. Any other PK concentrations that appear implausible to the Clinical Pharmacologist/Clinical PK/PD Scientist will not be excluded from the analysis. Any implausible data will be documented in the CSR.

If important protocol deviations occurred likely to affect the PK profile of participants as specified in Section 10.2.1, the impacted concentrations and PK parameters will be excluded from summary statistics and further statistical evaluation.

Any PK concentrations or PK parameters excluded from summary statistics will be included in participants listings and flagged; a reason for exclusion will be detailed in the CSR (e.g. a footnote or a table of exclusions). Any flags should be included in the study specific CDISC data sets.

PK concentrations and PK parameters excluded from summary statistics will not be included in mean/median figures. Mean plots will only contain values where  $n > 2$ .

#### **16.1.5 Estimation of Pharmacokinetic Parameters**

The computer program Phoenix® WinNonlin® version 6.4 PPD

PPD ) will be used to derive PK parameters applying noncompartmental analysis (NCA).

The statistical software SAS® (Statistical Analysis System, PPD windows version 9.1 or higher) will be used to generate additional PK parameters, produce tables, listings and figures.

### 16.1.5.1 Estimation of Pharmacokinetic Parameters in Plasma

PK parameters will be calculated using the actual elapsed time since dosing. In cases where the actual sampling time is missing, calculations may be performed using the scheduled time. Details (e.g. number of samples, participants affected) will be described in the CSR. In cases actual dosing time is missing, scheduled time might be used for NCA after performance of adequate plausibility checks and agreement with the sponsor. Decision and rationale should be included in the CSR. Otherwise, there will be no further imputation of missing data.

The following plasma PK parameters will be calculated where appropriate for tepotinib and its metabolites (MSC2571109A and MSC2571107A):

Symbol	Definition
$AUC_{0-\infty}$	The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at $t_{last}$ , as estimated using the linear regression from $\lambda_z$ determination. $AUC_{0-\infty} = AUC_{0-t_{last}} + C_{last\ pred} / \lambda_z$
$AUC_{0-t_{last}}$	The AUC from time zero (= dosing time) to the last sampling time ( $t_{last}$ ) at which the concentration is at or above the lower limit of quantification. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
$AUC_{0-24}$	The AUC from time zero (= dosing time) to timepoint 24 hours. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
$AUC_{0-24}/Dose$ (for parent drug only)	$AUC_{0-24}$ divided by actual dose.
$C_{max}$	Maximum observed concentration.
$C_{max}/Dose$ (for parent drug only)	$C_{max}$ divided by actual dose.
$t_{lag}$	The time prior to the first concentration at or above LLOQ.
$t_{max}$	The time to reach the maximum observed concentration collected during a dosing interval (the 1 <sup>st</sup> occurrence in the case of multiple/identical $C_{max}$ values).
$t_{1/2}$	Apparent terminal half-life. $t_{1/2} = \ln(2)/\lambda_z$
$\lambda_z$	Terminal first order (elimination) rate constant. Determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve.
$CL/F$ (parent drug only)	The apparent total body clearance of study intervention following extravascular administration. $CL/F = Dose_{po} / AUC_{0-\infty}$
$V_z/F$ (parent drug only)	The apparent volume of distribution during the terminal phase following extravascular administration. $V_z/F = Dose / (AUC_{0-\infty} \times \lambda_z)$ following single dose.
$AUC_{extra\%}$	The AUC from time $t_{last}$ extrapolated to infinity given as percentage of $AUC_{0-\infty}$ . $AUC_{extra\%} = (extrapolated\ area / AUC_{0-\infty}) \times 100$





- In case suitable regression cannot be performed, partial areas may be calculated using the actual sampling time provided it is within 10% of the actual sampling time.
- In cases BLQ concentrations occur at the end of the collection interval, these concentrations might be set to missing for calculations of partial AUCs. This is an exemption to the general BLQ handling rule and should be applied in case its application would result in estimation of implausible partial AUC values. Implausibility is considered in cases partial AUCs were greater than  $AUC_{0-\infty}$ .

The following PK parameters will be calculated for diagnostic purposes and listed, but will not be summarized:

- First ( $\lambda_z$  low) and last ( $\lambda_z$  up) time point of the time interval of the log-linear regression to determine  $\lambda_z$ .
- Number of data points ( $N\lambda$ ) included in the log-linear regression analysis to determine  $\lambda_z$ .
- Goodness of fit statistic (adjusted Rsq) for calculation of  $\lambda_z$ .
- AUC from time  $t_{last}$  extrapolated to infinity given as percentage of  $AUC_{0-\infty}$ . ( $AUC_{extra\%}$ )
- Span ratio of interval over which  $t_{1/2}$  was estimated/ $t_{1/2}$

The regression analysis should contain data from at least 3 different time points in the terminal phase consistent with the assessment of a straight line on the log-transformed scale. Phoenix WinNonlin “best fit” methodology will be used as standard. If warranted, further adjustment may be made by the pharmacokineticist, after agreement with the Sponsor. The last quantifiable concentration  $>LLOQ$  should always be included in the regression analysis, while the concentration at  $t_{max}$  and any concentrations BLQ which occur after the last quantifiable data point  $>LLOQ$  should not be used.

If  $AUC_{extra\%} > 20\%$  and/or the coefficient of correlation (Rsq adj) of  $\lambda_z$  is  $< 0.8$  and/or the observation period over which the regression line is estimated (span ratio) is less than 2-fold the resulting  $t_{1/2}$ , the rate constants and all derived parameters (e.g.  $t_{1/2}$ ,  $AUC_{0-\infty}$ , CL etc.) will be listed, flagged and included in the parameter outputs. Should more than 10% of subjects be flagged for  $AUC_{extra}$  and/or Rsq adj (for a particular analyte), a sensitivity analysis excluding flagged parameters may be performed after discussion with the Sponsor.

## **16.1.6 Presentation of PK Concentration and PK Parameter Data**

### **16.1.6.1 Listings and Tables**

The following PK tables will be produced (PK Analysis Set):

- Descriptive statistics of concentrations by analyte, matrix, study intervention (day)
- Descriptive statistics of PK parameters by analyte, matrix, study intervention (day)

The following PK Listings will be produced (Safety Analysis Set):

- Individual concentrations by analyte, matrix, day and study intervention (day)

- Individual PK parameters by analyte, matrix, day and study intervention (day)
- PK Sampling date, actual time, nominal time, deviation from time, percentage time deviation by participant, analyte, matrix and study intervention (day) sorted in chronological order
- Phoenix WinNonlin NCA Core Output

#### **16.1.6.2 Graphical Summaries and Individual plots (PK Analysis Set)**

The following graphical summaries and individual plots will be provided for tepotinib and its metabolites (MSC2571109A and MSC2571107A) as well as carbamazepine, if not stated otherwise:

- Overlaid individual plasma concentration versus time plots on linear and semi-log scale, using actual times; by analyte and study intervention (day);
- Overlaid individual plasma concentration versus time plots by participant and analyte on linear and semi-log scale using actual times. If any post-dose concentration is BLQ the line representing LLOQ will be added to the semi-log plots.
- Arithmetic mean concentration time plots; linear ( $\pm$ SD for arithmetic mean) and semi-log; using scheduled (nominal) time points by analyte, matrix and study intervention (day); if any post-dose concentration is BLQ the line representing LLOQ will be added to the semi-log plots
- Boxplots for primary PK parameters  $AUC_{0-\infty}$ ,  $AUC_{0-t_{last}}$ ,  $C_{max}$  of tepotinib by study intervention (day) and analyte.
- Spaghetti plot of primary PK parameters  $AUC_{0-\infty}$ ,  $AUC_{0-t_{last}}$ ,  $C_{max}$  of tepotinib by study intervention (day) and analyte

**17**

**References**

Not applicable.

**18**

## **Appendices**

Not applicable